ストックスクリーナーアプリを入手
26.52
1.08%
-0.29
アフターアワーズ：
26.52
Zymeworks Inc. (ZYME) 最新ニュース
Theravance Biopharma Insider Brett Grimaud Reports Complete Share Cancellation Following Zymeworks Merger - Kalkine Media
Vancouver biotech Zymeworks closes US$929M Theravance deal - Business in Vancouver
Zymeworks Inc. (ZYME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Zymeworks closes out acquisition of Theravance for USD 929m - AllSci
What Does the Theravance Acquisition Add for Zymeworks (NASDAQ:ZYME)? - Kalkine Media
Zymeworks Completes Acquisition of Theravance Biopharma - Indovizka.com
Zymeworks Finalizes Merger with Theravance Biopharma and Launches $350M Senior Secured Notes - Kalkine Media
Zymeworks completes acquisition of Theravance Biopharma By Investing.com - Investing.com Canada
Zymeworks completes acquisition of Theravance Biopharma - Investing.com
Zymeworks Raises $350 Million Notes and Launches Ampreloxetine CVR - TradingView
A $350 million debt issue helped fund Zymeworks (ZYME)'s Theravance acquisition, with cash due per eligible share. - Stock Titan
Squarepoint Ops LLC Reduces Holdings in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks stock gains on fresh Wolfe Research coverage - AD HOC NEWS
Zymeworks stock gains on merger approval and a $41 target - AD HOC NEWS
Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Theravance Biopharma Shareholders Endorse Merger with Zymeworks Inc. - kalkinemedia.com
Zymeworks Stock Price Forecast. Should You Buy ZYME? - StockInvest.us
Theravance Biopharma shareholders approve merger with Zymeworks - Investing.com
Theravance Biopharma shareholders approve merger with Zymeworks By Investing.com - Investing.com UK
Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow (NASDAQ:ZYME) - Seeking Alpha
Zymeworks stock gains as Theravance deal and valuation draw investor focus - AD HOC NEWS
Zymeworks Inc. (ZYME): Investor Outlook Reveals 50% Upside Potential In Biotech Arena - DirectorsTalk Interviews
Why Is Wolfe Research Starting Coverage On Zymeworks (NASDAQ:ZYME)? - Kalkine Media
Wolfe Research Begins Coverage on Zymeworks (NASDAQ:ZYME) - MarketBeat
Zymeworks Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 238,026 Shares of Zymeworks Inc. $ZYME - MarketBeat
Wellington Management Group LLP Takes $2.88 Million Position in Zymeworks Inc. $ZYME - MarketBeat
Legal & General Group Plc Makes New $1.13 Million Investment in Zymeworks Inc. $ZYME - MarketBeat
Bank of New York Mellon Corp Acquires New Holdings in Zymeworks Inc. $ZYME - MarketBeat
JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00 - MarketBeat
Zymeworks (ZYME) Falls 3.7% to $29.9 as Shares Slip Below $30RVOL Breakout - careplusvn.com
Zymeworks (NASDAQ:ZYME) Hits New 1-Year HighTime to Buy? - MarketBeat
Zymeworks stock hits 52-week high at 30.75 USD - Investing.com
Zymeworks stock hits 52-week high at 30.75 USD By Investing.com - Investing.com Nigeria
ZJM stock holds near its latest trade. Zymeworks data still drives the setup - AD HOC NEWS
Enterprise value to revenue forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Man Group plc Invests $5.51 Million in Zymeworks Inc. $ZYME - marketbeat.com
4,251,030 Shares in Zymeworks Inc. $ZYME Bought by BlackRock Inc. - marketbeat.com
Zymeworks stock holds near $28.27 as market cap tops $2.01 billion - ad-hoc-news.de
FY2026 EPS Estimates for Zymeworks Raised by HC Wainwright - MarketBeat
Is Zymeworks (ZYME) Stock Fully Priced After Its 301% Run? - Yahoo Finance
Zymeworks shifts to revenue growth after FDA ap... - Pluang
HC Wainwright Has Strong Estimate for Zymeworks Q3 Earnings - marketbeat.com
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval - Seeking Alpha
Zymeworks moves higher as Street cheers Ziihera regimen approval - Seeking Alpha
Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens - Sahm
Zymeworks stock hits 52-week high at 29.81 USD By Investing.com - Investing.com South Africa
Zymeworks stock rating reiterated at Market Outperform by Citizens - Investing.com India
Zymeworks Announces FDA Approval of Ziihera-Based Regimens for First-Line HER2-Positive Gastroesophageal Adenocarcinoma and $250 Million Milestone Payment from Jazz Pharmaceuticals - quiverquant.com
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma - NTB Kommunikasjon
Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab - Yahoo Finance
Theravance (NASDAQ: TBPH) sets vote on cash buyout with ampreloxetine CVR upside - Stock Titan
Enterprise value to revenue forward of Zymeworks Inc. – SWB:ZA8 - TradingView
Zymeworks (ZYME) Session Brief: Climbs 2.69% to $25.99 in the Latest Session; Reference Levels: $24.69 and $27.29 Define the Nearby Reference Levels at the ClosePCR Spike - vinanet.vn
How Zymeworks’ Bigger Loss, Buyback and Milestones Pivot At Zymeworks (ZYME) Has Changed Its Investment Story - simplywall.st
ZYME Q2 2026 Earnings: Wider-than-Expected Loss of -$0.62 per Share Reflects Clinical-Stage InvestmentProduct Revenue Analysis - vinanet.vn
Zymeworks Inc. (ZYME) stock price, news, quote and history - Yahoo Finance Australia
Q3 Earnings Estimate for Zymeworks Issued By HC Wainwright - MarketBeat
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):